Masimo Corporation (MASI) - Stock Analysis
Last updated: Jun 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Definitive $180 cash takeover by Danaher announced 2026-02-17 created a large premium and sharp momentum; stock trades below the deal price with near-term catalysts (2/26 earnings call, evolving shareholder litigation) driving an attractive event-arbitrage spread over the next few days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Profit rebound ⢠Strong liquidity ⢠High valuation MASI's near-term earnings and cash flow improved sharply in Q1 2026, with strong liquidity and lower leverage, but full-year profitability remains weak and the stock still looks expensive.
Price Behavior
Key Price Behavior Insights: ⢠Tight range ⢠Firm support ⢠Capped upside Support Level: $178.4-$178.5 Resistance Level: $178.8-$178.9 MASI has traded sideways with a slight upward tilt over the last month, holding support near $178.4-$178.5 but repeatedly stalling below $178.8-$178.9, so it remains rangebound with no confirmed breakout.
Sentiment & News
Key News Insights: ⢠Relative valuation ⢠Peer screening ⢠No catalysts Masimo's recent MASI headlines mainly reflect repeated valuation comparisons with Integra LifeSciences, signaling ongoing investor focus on relative value rather than new company-specific developments .
AI Summary
MASI should now be viewed primarily as a Danaher deal-arbitrage position rather than a standalone medtech growth story, because the main upside is tied to deal completion and a narrow spread to cash while strong cash flow and margins mostly provide downside support if scrutiny, delays, or re-trading emerge. #M&Aâ
Description
Masimo designs and manufactures noninvasive physiological monitoring devices and hospital automation software sold worldwide. Its clinical product set includes advanced pulse oximetry that addresses motion and low-perfusion limits of conventional oximeters, a multi-parameter platform for hemoglobin species and oxygen-related metrics, EEG-based brain function monitoring, capnography and gas analyzers, regional oximetry and hemodynamic tools, as well as connectivity and hospital surveillance solutions. The company sells through direct sales, distributors and OEM partners to hospitals, emergency and home care providers, long-term care facilities, physician offices, veterinarians and consumers; it was founded in 1989 and is headquartered in Irvine, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 19 | Feb 26 | MASI | Masimo Corporation | Definitive $180 cash takeover by Danaher announced 2026-02-17 created a large premium and sharp momentum; stock trades below the deal price with near-term catalysts (2/26 earnings call, evolving shareholder litigation) driving an attractive event-arbitrage spread over the next few days. | Closed | -0.1% |
| Nov 17 | Nov 24 | MASI | Masimo Corporation | Q3 2025 earnings beat with strong margin expansion, increased free cash flow, positive patent infringement ruling, extended FDA clearances, and constructive technical trends near moving averages underpin Masimo as a near-term growth opportunity. | Closed | -1.0% |